Triple-negative breast cancer (TNBC) remains the most challenging breast cancer subtype to treat not only due to the lack of ER, PgR and HER2 as therapeutic targets but also to the high heterogeneity that makes the management of this disease even more difficult [5]. The gene discussed is ERBB2; the disease is breast carcinoma.